Adjuvant (I-III, A-C) Colon Cancer

Second Large Study Confirms Oncotype DX Can Predict Recurrence in Stage 2 Colon Cancer (04-22-2013)

Results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test confirm that Recurrence Score® (RS) results improve the ability to differentiate high recurrence risk disease from low recurrence risk disease, beyond... Continue Reading

Oncotype DX in Colon Cancer May Reduce Medical Costs and Improve Patient Wellbeing (02-20-2013)

The results of two studies evaluating Oncotype DX were presented at the 2013 Gastrointestinal Cancers Symposium in San Francisco and the data indicated that the colon cancer test may reduce medical costs, improve patient wellbeing, and change treatment... Continue Reading

Oncotype Validated in Stage II and III Colon Cancer (01-3-2013)

The Oncotype DX® Recurrence Score® (RS) results predict recurrence risk in stage II and III colon cancer and may better inform adjuvant therapy decisions in this population, according to the results of a validation study published in the Journal of... Continue Reading

Aspirin May Prolong Life in PIK3CA-Mutated Colorectal Cancers (11-6-2012)

Daily aspirin use improves survival among patients with mutated-PIK3CA colorectal cancer, according to the results of a study published in the New England Journal of Medicine. Colorectal cancer remains the second leading cause of cancer-related death... Continue Reading

Oncotype DX Predicts Risk of Colon Cancer Recurrence (10-2-2012)

Among patients with Stage II or Stage III colon cancer, the Oncotype DX colon cancer test provides information about risk of cancer recurrence and overall survival, and may help guide treatment decisions. These results were presented at the European Society... Continue Reading

Adjuvant Therapy May Offer Survival Benefit in Older Patients with Colorectal Cancer (09-11-2012)

Adjuvant chemotherapy appears to offer a survival benefit to patients aged 75 years or older who have surgically resected colorectal cancer, according to the results of a study published in the Journal of Clinical Oncology. Colorectal cancer is the second... Continue Reading

Oncotype DX Predicts Recurrence Risk in Stage II and Stage III Colon Cancer (06-11-2012)

Among patients with Stage II or Stage III colon cancer, the Oncotype DX colon cancer test provides information about risk of cancer recurrence and may help guide treatment decisions. These results were presented at the 2012 Annual Meeting of the American... Continue Reading

Physical Activity Linked to Reduced Mortality in Breast and Colon Cancer (05-22-2012)

Physical activity is associated with reduced mortality in patients with breast and colon cancer, according to a study published in the Journal of the National Cancer Institute.[1] So far, there is insufficient evidence to draw the same conclusion with... Continue Reading

Erbitux May Not Benefit Stage III Colon Cancer (04-6-2012)

Among patients with Stage III colon cancer, the addition of Erbitux® (cetuximab) to adjuvant (post-surgery) chemotherapy did not improve outcomes. These results were published in the Journal of the American Medical Association. Stage III colon cancer... Continue Reading

Oncotype DX Colon Cancer Test Changes Treatment in One-Third of Patients (01-20-2012)

A survey of oncologists suggests that the Oncotype DX colon cancer test changes treatment recommendations for roughly one-third of patients with Stage II colon cancer. These results will be presented at the 2012 Gastrointestinal Cancers Symposium. Gene... Continue Reading

« Previous PageNext Page »